These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29185199)

  • 1. Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Yagi S; Aihara KI; Kondo T; Kurahashi K; Yoshida S; Endo I; Fukuda D; Nakaya Y; Suwaki KI; Takeji T; Wada T; Salim HM; Hama S; Matsuura T; Ise T; Kusunose K; Yamaguchi K; Tobiume T; Yamada H; Soeki T; Wakatsuki T; Matsuhisa M; Shimabukuro M; Akaike M; Sata M
    Adv Ther; 2018 Jan; 35(1):124-134. PubMed ID: 29185199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
    Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES
    Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
    Dennis JM; Young KG; McGovern AP; Mateen BA; Vollmer SJ; Simpson MD; Henley WE; Holman RR; Sattar N; Pearson ER; Hattersley AT; Jones AG; Shields BM;
    Lancet Digit Health; 2022 Dec; 4(12):e873-e883. PubMed ID: 36427949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors.
    Shimizu N; Ogawa A; Hayashi A; Shichiri M
    J Diabetes Complications; 2022 Jul; 36(7):108225. PubMed ID: 35690574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study.
    Hirai T; Kawagoe Y; Kei M; Ogawa R; Itoh T
    Biol Pharm Bull; 2020; 43(5):782-787. PubMed ID: 32378557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: A retrospective cohort study.
    Scoccimarro D; Cipani G; Dicembrini I; Mannucci E
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3727. PubMed ID: 37776322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
    Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus.
    Kurinami N; Sugiyama S; Nishimura H; Morita A; Yoshida A; Hieshima K; Miyamoto F; Kajiwara K; Jinnouchi K; Jinnouchi T; Jinnouchi H
    Clin Drug Investig; 2018 Jan; 38(1):19-27. PubMed ID: 29098566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
    Chino Y; Kuwabara M; Hisatome I
    J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of sodium-glucose co-transporter-2 inhibitors in Chinese patients with type 2 diabetes mellitus.
    Chan WB
    Singapore Med J; 2019 Jun; 60(6):309-313. PubMed ID: 30402655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
    Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
    J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
    Jinnouchi H; Nozaki K; Watase H; Omiya H; Sakai S; Samukawa Y
    Adv Ther; 2016 Mar; 33(3):460-79. PubMed ID: 26846284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
    Martens P; Janssens J; Ramaekers J; Dupont M; Mullens W
    Acta Cardiol; 2020 Jun; 75(3):211-217. PubMed ID: 30736724
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.